Press Releases Year None2024202320222021 April 9, 2024 NewAmsterdam Pharma Enrolls Over 9,000 Patients in Pivotal Phase 3 PREVAIL Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients with Established Atherosclerotic Cardiovascular Disease April 1, 2024 NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer March 25, 2024 NewAmsterdam Pharma to Present New Analysis from the Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe at 2024 American College of Cardiology Congress March 12, 2024 NewAmsterdam Pharma Doses First Patient in Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib and Ezetimibe in Patients with HeFH and/or ASCVD February 28, 2024 NewAmsterdam Pharma Reports Full Year 2023 Financial Results and Provides Corporate Update February 26, 2024 NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in March February 13, 2024 NewAmsterdam Pharma Announces Pricing of $175.3 Million Public Offering of Ordinary Shares and Pre-Funded Warrants February 13, 2024 NewAmsterdam Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants February 1, 2024 NewAmsterdam Pharma to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference January 8, 2024 NewAmsterdam Pharma Appoints William H. Lewis, J.D., M.B.A. as Chair of its Board of Directors Pagination Current page 1 Page 2 Next page next › Last page last » Displaying 1 - 10 of 11
April 9, 2024 NewAmsterdam Pharma Enrolls Over 9,000 Patients in Pivotal Phase 3 PREVAIL Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients with Established Atherosclerotic Cardiovascular Disease
April 1, 2024 NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer
March 25, 2024 NewAmsterdam Pharma to Present New Analysis from the Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe at 2024 American College of Cardiology Congress
March 12, 2024 NewAmsterdam Pharma Doses First Patient in Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib and Ezetimibe in Patients with HeFH and/or ASCVD
February 28, 2024 NewAmsterdam Pharma Reports Full Year 2023 Financial Results and Provides Corporate Update
February 13, 2024 NewAmsterdam Pharma Announces Pricing of $175.3 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
February 13, 2024 NewAmsterdam Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants
February 1, 2024 NewAmsterdam Pharma to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
January 8, 2024 NewAmsterdam Pharma Appoints William H. Lewis, J.D., M.B.A. as Chair of its Board of Directors
